Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
383 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014', provides an overview of the Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 6 Chronic Lymphocytic Leukemia (CLL) Overview 7 Therapeutics Development 8 Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 10 Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 16 Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 18 Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 22 Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 27 Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 29 Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 89 Drug Profiles 108 Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 274 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 356 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 361 Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 362 Appendix 370
List of Tables Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2014 20 Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2014 21 Number of Products under Development by Companies, H2 2014 23 Number of Products under Development by Companies, H2 2014 (Contd..1) 24 Number of Products under Development by Companies, H2 2014 (Contd..2) 25 Number of Products under Development by Companies, H2 2014 (Contd..3) 26 Number of Products under Development by Companies, H2 2014 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H2 2014 29 Comparative Analysis by Late Stage Development, H2 2014 30 Comparative Analysis by Clinical Stage Development, H2 2014 31 Comparative Analysis by Early Stage Development, H2 2014 32 Comparative Analysis by Unknown Stage Development, H2 2014 33 Products under Development by Companies, H2 2014 34 Products under Development by Companies, H2 2014 (Contd..1) 35 Products under Development by Companies, H2 2014 (Contd..2) 36 Products under Development by Companies, H2 2014 (Contd..3) 37 Products under Development by Companies, H2 2014 (Contd..4) 38 Products under Investigation by Universities/Institutes, H2 2014 39 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 40 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2014 41 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H2 2014 42 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc., H2 2014 43 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2014 44 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H2 2014 45 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd., H2 2014 46 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech, Inc., H2 2014 47 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H2 2014 48 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2014 49 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co., Inc., H2 2014 50 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H2 2014 51 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 52 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amorfix Life Sciences Ltd., H2 2014 53 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 54 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2014 55 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eisai Co., Ltd., H2 2014 56 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz Inc., H2 2014 57 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 58 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2014 59 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 60 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H2 2014 61 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2014 62 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H2 2014 63 Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2014 64 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celldex Therapeutics, Inc., H2 2014 65 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2014 66 Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H2 2014 67 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 68 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Limited, H2 2014 69 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H2 2014 70 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H2 2014 71 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics S.A., H2 2014 72 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 73 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc., H2 2014 74 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H2 2014 75 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2014 76 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectis S.A., H2 2014 77 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 78 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mirna Therapeutics, Inc., H2 2014 79 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Angstrom Pharmaceuticals, Inc., H2 2014 80 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2014 81 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprea AB, H2 2014 82 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eagle Pharmaceuticals Inc., H2 2014 83 Chronic Lymphocytic Leukemia (CLL) - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 84 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Fountain Biopharma Inc., H2 2014 85 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics, Inc., H2 2014 86 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprogen, Inc., H2 2014 87 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma, Inc., H2 2014 88 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lead Discovery Center GmbH, H2 2014 89 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H2 2014 90 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Conkwest, Inc., H2 2014 91 Chronic Lymphocytic Leukemia (CLL) - Pipeline by The International Biotechnology Center (IBC) "Generium", H2 2014 92 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech, LLC, H2 2014 93 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Curaxys, S.L., H2 2014 94 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 95 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics, Inc., H2 2014 96 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2014 97 Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H2 2014 98 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 99 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Senhwa Biosciences, Inc., H2 2014 100 Assessment by Monotherapy Products, H2 2014 101 Assessment by Combination Products, H2 2014 102 Number of Products by Stage and Target, H2 2014 105 Number of Products by Stage and Mechanism of Action, H2 2014 111 Number of Products by Stage and Route of Administration, H2 2014 116 Number of Products by Stage and Molecule Type, H2 2014 119 Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H2 2014 286 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2014 368 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2014 369 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..2), H2 2014 370 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..3), H2 2014 371 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..4), H2 2014 372 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2014 373
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
